Empowering the Entire CGT Value Chain: Building a Robust Raw Material Foundation from Research to GMP Manufacturing

Bridging the Critical Gap in Cell and Gene Therapy Development

The rapidly growing demand for high-quality biological raw materials continues to accelerate innovation in disease research and therapeutic development. In 2026, Cell and Gene Therapy (CGT) was officially included in China's Government Work Report for the first time, signaling its elevation to a national strategic industry. At the same time, the global cell therapy raw materials market is expanding rapidly — growing from USD 5.07 billion in 2025 to USD 6.1 billion in 2026, and projected to reach USD 12.75 billion by 2030, with a compound annual growth rate (CAGR) exceeding 20%.

From early-stage scientific discovery to commercial-scale manufacturing, the CGT industry is facing an unprecedented demand for high-quality, scalable, and regulatory-compliant raw materials. However, a long-standing challenge still limits the efficient translation of innovative therapies: the significant "quality gap" between research-grade reagents and clinical manufacturing materials.

Researchers frequently encounter difficulties reproducing successful laboratory protocols during process scale-up, while therapy developers face costly delays and regulatory risks caused by raw material changes during clinical transition. Achieving a seamless connection from research to clinical manufacturing has therefore become a critical bottleneck in accelerating CGT commercialization.

From Source to Final Product: A Fully Integrated Internal Production Control System

To address these industry challenges, we have established a fully integrated internal production control system covering the entire workflow from source material development to final product release. This system ensures exceptional product quality, batch-to-batch consistency, and long-term supply reliability across every stage of CGT development.

We provide comprehensive cytokine and cell culture reagent solutions supporting the full continuum from basic research to GMP manufacturing. The portfolio includes three clearly defined product grades:

- Research Grade (RG)
- Premium Grade (PG / Pre-GMP)
- GMP Grade

Each grade is specifically designed to meet the technical, operational, and regulatory requirements of different development stages, helping researchers and therapy developers balance quality standards, compliance readiness, and cost efficiency while accelerating the transition from scientific discovery to clinical application.

Research Grade (RG): Designed for Reliable and Reproducible Scientific Research

RG products are specifically developed for universities, research institutes, and early-stage discovery laboratories, with a strong focus on improving experimental reproducibility. Through stringent quality control, ultra-low endotoxin levels, and animal-origin-free (AOF) manufacturing processes, RG products deliver outstanding reliability and stability for applications such as immunology research, stem cell differentiation, and organoid culture.

Premium Grade (PG): Supporting Early Process Development and Clinical Translation

PG products are designed for early-stage drug development and translational research. Manufactured using the same cell clones and core production processes as GMP-grade materials, PG products are produced under animal-origin-free conditions to support cell banking, process development, and preclinical evaluation.

The key advantage of PG products lies in enabling a smooth transition from research to clinical manufacturing. By minimizing risks associated with animal-derived components and improving process consistency, PG solutions help biotechnology and cell therapy companies establish scalable and compliance-ready manufacturing workflows at an early stage.

GMP Grade: Enabling Clinical Manufacturing and Commercial Production

GMP-grade products are manufactured under strict cGMP standards to support clinical-stage development and commercial manufacturing requirements. These products are backed by a comprehensive quality management system, fully traceable supply chains, and extensive regulatory documentation support.

GMP-grade materials are suitable for clinical manufacturing, CTM (Clinical Trial Material) production, and commercial cell therapy manufacturing, providing pharmaceutical companies with reliable raw materials that comply with global regulatory expectations while ensuring product safety, consistency, and scalability.

A Strategic Grading System Designed for Long-Term Translation

This grading strategy is not simply a conventional "high-middle-low" product classification. Instead, it represents a systematic "begin-with-the-end-in-mind" development approach.

All three product grades share the same cell clone origins and core manufacturing workflows. The primary differences lie in the depth of quality control, documentation completeness, and regulatory compliance standards. This means users can smoothly transition from RG to PG and ultimately to GMP-grade materials without changing the underlying technical platform.

For academic researchers, RG products provide a robust and highly reproducible experimental foundation. For biotechnology and cell therapy developers, beginning with PG products enables a "develop once, scale continuously" strategy, allowing early-stage process development results to be directly transferred into GMP manufacturing while avoiding costly redevelopment. For pharmaceutical companies entering clinical trials or commercial production, GMP-grade materials serve as a critical gateway to global regulatory compliance and market access.

Supporting Academic and Research Communities with High-Quality RG Products

Research Grade Products: Built for Reproducibility and Research Confidence

Basic research remains the foundation of scientific innovation. In cutting-edge fields such as immunology, stem cell differentiation, and organoid development, experimental reproducibility is one of the most important indicators of research quality.

However, many researchers have experienced inconsistent results caused by variations in cytokine batches, unexpected stem cell differentiation, or unstable cell culture performance. Our RG products are specifically designed to address these challenges through rigorous quality standards and highly controlled manufacturing processes.

Key Features and Advantages

- Native sequence and tag-free design to preserve natural protein conformation and biological functionality
- Biological activity calibrated according to WHO/NIBSC standards
- Comprehensive quality control for every batch, including protein content, purity, endotoxin testing, and cell-based bioactivity assays
- Ultra-low endotoxin levels (<0.01 EU/μg)
- Sterile filtration through 0.2 μm filters for enhanced safety assurance
- Animal-origin-free (AOF) manufacturing processes applied to the majority of research-grade products

Comprehensive Product Portfolio for Advanced Cell Therapy Research

The RG product portfolio includes cytokines, magnetic beads, matrix proteins, and additional cell culture reagents that support differentiation of pluripotent stem cells (PSC) into immune cells (HSCs, T cells, NK cells), neural cells, and pancreatic islet cells. These products are also widely used for the expansion and culture of T cells, NK cells, dendritic cells (DCs), and macrophages.

[Click to Explore the Products]

By combining high reproducibility, scalable manufacturing compatibility, and translational continuity, We help global CGT researchers and developers establish a stronger and more efficient pathway from discovery to clinical manufacturing.

FAQ:

Q1: What Are the Differences Between Research Grade, Premium Grade, and GMP Grade Raw Materials in CGT?

A: Research Grade (RG), Premium Grade (PG), and GMP Grade are three quality levels of CGT raw materials designed for research, process development, and clinical/commercial manufacturing, respectively. They share the same cell source and core manufacturing process but differ in quality control, regulatory compliance, and documentation support, enabling a smooth transition from research to GMP production.

Q2: What Is the Role of Premium Grade (PG) in Cell and Gene Therapy Development?

A: Premium Grade (PG) products are designed for early process development and preclinical research. Manufactured using the same cell clones and core production processes as GMP Grade products, they help reduce process-change risks and support a smoother transition to GMP manufacturing.

Q3: What Are the Key Quality Attributes of Research Grade (RG) Cytokines?

A: Research Grade (RG) cytokines feature native, tag-free protein design, WHO/NIBSC-calibrated bioactivity, comprehensive batch testing, ultra-low endotoxin levels (<0.01 EU/μg), 0.2 μm sterile filtration, and animal-origin-free (AOF) manufacturing to improve experimental reproducibility and consistency.

Q4: What Are GMP Grade Raw Materials Used for in Cell Therapy Manufacturing?

A: GMP Grade raw materials are produced in compliance with cGMP standards and supported by a complete quality management system, traceable supply chain, and regulatory documentation. They are used for Clinical Trial Material (CTM) production and commercial cell therapy manufacturing, ensuring product consistency, safety, and scalability.

Q5: Why Does the CGT Industry Need a Unified Research-to-GMP Raw Material Platform?

A: A significant quality gap often exists between research-grade and clinical-grade materials, creating challenges during process scale-up and clinical translation. A unified RG—PG—GMP platform enables continuity from research to commercial manufacturing, reduces process redevelopment risks, and accelerates CGT product development.

Resources: